Health

New COVID treatment shows efficacy against omicron: Spain’s PharmaMar

Spain's PharmaMar said on Tuesday trials made in vitro and on animals showed its Plitidepsin drug had positive antiviral effects on the variants of COVID-19, including omicron.

The results of Phase I trials have shown the drug, also known as Aplidin, had a powerful antiviral activity against all the variants in vitro and a distribution into the lungs of animals tested, resulting in a 99 percent reduction of viral load in the lungs, the company said.

For more coronavirus news, visit our dedicated page.

The results of the trials were released in a paper published in the scientific journal Life Science Alliance, PharmaMar said.

The paper also reported positive effects of Phase I and II trials on patients.

"All data we have seen so far with Plitidepsin corroborate our initial hypothesis of its activity as antiviral," PharmaMar's Jose Maria Fernandez Sousa said in a statement.

The drug is being tested in final Phase III trials on patients.

Shares in PharmaMar rose 5.3 percent in early trading.

Plitidepsin is a drug developed by PharmaMar originally to treat cancer but has an effect as an antiviral.

Poland’s total COVID-19 death toll passes 100,000 amid fourth wave

‘Deltacron’ likely result of lab error: Experts

Health

‘Just in case’ use of antibiotics was rife during COVID-19, says UN health agency

Antibiotics saw “extensive overuse” globally among hospitalized COVID-19 patients during the pandemic without improving clinical outcomes, while also potentially exacerbating the already serious and growing threat of antimicrobial resistance, the UN World Health Organization (WHO) said on Friday.

Health

Teen alcohol and nicotine use in Europe is up, WHO urges preventive measures

Substance use is on the rise among teenagers in Europe, Central Asia and Canada and girls now match or even exceed boys when it comes to smoking and drinking, the World Health Organization (WHO) said in a new report on Thursday.

Health

Gender therapy review reveals devastating impacts on teens

A top Human Rights Council-appointed expert has welcomed the decision by all health authorities in the United Kingdom to halt the routine use of puberty-blockers offered to children as part of gender transition services, amid a sharp increase more widely in the number of teenage girls seeking such treatment and concerns that it might disrupt brain development.